The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

In this episode, Christopher Bunick, MD, PhD, discusses a paper he recently co-authored, which explores JAK inhibitor safety compared to traditional systemic therapies for atopic dermatitis.

Related Videos
Related Content

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Treating Atopic Dermatitis in the Winter

November 14th 2022

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Treating Atopic Dermatitis in the Winter

November 14th 2022

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

The Cutaneous Connection: Treating Atopic Dermatitis in the Winter

November 14th 2022

Vitamin D Supplements During Pregnancy May Reduce Eczema in Infants

March 23rd 2023

Pregnant Women with Skin Conditions May Require Dermatologic Intervention

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.